FCGR2A and neoplasm: Hierarchical clustering analyses validated FCGR2A’s clinical discriminative power, achieving near-perfect separation of tumor/normal specimens (silhouette width=0.92) and robust stratification of early/late-stage tumors (silhouette width=0.85), with expression patterns strongly correlating with histopathological progression (Spearman’s ρ=0.81, p=1.3×10-6) (70).